From IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer · · IEEE EMBS
“We embarked on a study a few years ago called Preserve to show that the product can be used safely and effectively to treat men with intermediate risk prostate cancer. So we wanted to give the population between that another option to be treated using our nano knife, which our study proved could treat the organ, control the cancer, and reduce the chances of men having incontinence or impotence post treatment almost to zero.”
On , James Clemmer, Chief Executive Officer, President & Director at ANGIODYNAMICS INC, spoke about prostate cancer treatment during IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer on IEEE EMBS.
In a December 2025 interview with IEEE Pulse, AngioDynamics CEO Jim Clemmer discussed the company's transformation into a science-driven MedTech innovator focused on cancer and cardiovascular disease. Clemmer described the company's strategy of active portfolio management, stating, "It took active portfolio management, which is easy to say, hard to do. So, we divested some assets that actually provided revenue and profit for the company." He also highlighted the company's market performance, saying, "Now five years post launch, we're already taking a number three position in market share, past three of those really big powerful companies." Clemmer emphasized the importance of physician collaboration, clinical evidence, and early reimbursement strategy in bringing breakthrough medical technologies to market. He noted that AngioDynamics obtained a CPT-1 code before receiving 510K clearance, which he described as unusual in his experience. Clemmer also discussed the challenges of market access, stating, "Market access can be really, really challenging and teams need to really think that through and have a really good strategy." He shared his background starting as a sales representative in 1989 and described how the company engaged with physicians to build trust and support for its products.